A carregar...
Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis
BACKGROUND: Inhibition of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) is a novel choice for the treatment of renal anemia, and an oral HIF-PH inhibitor roxadustat was approved for renal anemia. Roxadustat has high affinity to thyroid hormone receptor beta, which may affect thyroid hormone h...
Na minha lista:
| Publicado no: | BMC Nephrol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7981856/ https://ncbi.nlm.nih.gov/pubmed/33743638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-021-02304-2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|